Swiss speciality chemicals maker Clariant and US investment firm Clayton, Dubilier & Rice are in talks to buy American chemicals company Ashland in an all-cash deal worth about $3.39 billion, Bloomberg News reported on Sunday, citing people familiar with the matter.
The deal would value Ashland close to its share price on Friday, according to the report. No final decision has been made, and the discussions could still fall through or be overtaken by another suitor, Bloomberg said. Clariant and Ashland declined to comment on the report, and CD&R could not immediately be reached. Reuters, which carried the report, said it could not immediately verify it.
The talks are the latest step in a sale process that began in the summer, when Ashland put itself up for sale after coming under pressure from activist investors who argued the company was undervalued.
Activist fund Ancora Alternatives built a significant stake in June and publicly urged Ashland to conduct a full strategic review, including a sale of the whole business. Ancora argued that a sale could deliver at least $76 a share, more than 30 per cent above the price at the time, after the stock had fallen roughly half from its December 2022 peak. The two sides later reached a cooperation agreement in late July that added two new directors to Ashland’s board.
A string of other buyers has also circled the Delaware-based company. Private equity firms Advent, Apollo Global Management and Carlyle Group have all had contact with Ashland, and Standard Industries, its largest shareholder with a stake of nearly 10 per cent, has also been linked with an approach. Standard Industries bought chemicals giant W.R. Grace in 2021.
CD&R has teamed up with Clariant for its bid. Clariant would probably face competition problems if it tried to buy Ashland on its own, because the two companies overlap in areas such as personal care ingredients, according to people familiar with the process cited in earlier reports. Initial bids for Ashland were collected in early October.
Ashland makes speciality ingredients used in personal care products, medicines and food, counting L’Oréal, Estée Lauder and Pfizer among its customers. A deal would combine those businesses with Clariant’s care chemicals operations, which the Swiss company said had helped lift its sales in the third quarter even as restructuring charges weighed on profits.
For Clariant, a deal would cap a year of pressure on its own shares and operations. The company reported weaker-than-expected quarterly core profit earlier this month, blaming disruption in its catalysts business linked to the war in Iran, but said the impact was easing and maintained its outlook for 2026.
Sources: Reuters — “Clariant and CD&R in talks to buy chemicals firm Ashland, Bloomberg News reports” (https://www.reuters.com/sustainability/sustainable-finance-reporting/clariant-cdr-talks-buy-chemicals-firm-ashland-bloomberg-news-reports-2026-11-22/), reporting Bloomberg News.
